In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Nuvalent (NUVL – Research Report). The company’s shares opened today at $59.18.
Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Cardiff Oncology, and Puma Biotechnology. According to TipRanks, Frahm has an average return of 10.4% and a 42.34% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $75.17 average price target.
See Insiders’ Hot Stocks on TipRanks >>
NUVL market cap is currently $3.55B and has a P/E ratio of -30.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvalent (NUVL) Company Description:
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
Read More on NUVL:
- Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
- Nuvalent director sells $4.65M in common stock
- Nuvalent price target raised to $79 from $73 at BMO Capital
- Nuvalent 5.36M share Spot Secondary priced at $56.00
- Nuvalent price target raised to $69 from $42 at Leerink
